-
公开(公告)号：US20060153770A1
公开(公告)日：2006-07-13
申请号：US11378093
申请日：2006-03-17
申请人： Sally DeNardo , Patricia Burke , Gerald DeNardo , Simon Goodman , Siegfried Matzku , Kerstin Matzku
发明人： Sally DeNardo , Patricia Burke , Gerald DeNardo , Simon Goodman , Siegfried Matzku , Kerstin Matzku
IPC分类号： A61K51/00 , A61K39/395 , A61K31/33 , A61K38/12
CPC分类号： A61K45/06 , A61K31/33 , A61K38/12 , A61K51/1045 , A61K51/1096 , A61K2039/505 , C07K16/30 , C07K16/3092 , A61K2300/00
摘要： A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.
-
公开(公告)号：US07011967B1
公开(公告)日：2006-03-14
申请号：US10030688
申请日：2000-07-04
IPC分类号： C12N9/64
CPC分类号： C12N9/6424 , C07K2319/00
摘要： Seripancrin polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Seripancrin polypeptides and polynucleotides in diagnostic assays.
摘要翻译： 披露丝裂蛋白多肽和多核苷酸以及通过重组技术产生此类多肽的方法。 还公开了在诊断测定中利用塞来平凝胶多肽和多核苷酸的方法。
-
公开(公告)号：US06979726B1
公开(公告)日：2005-12-27
申请号：US08362951
申请日：1994-12-23
申请人： Ilka von Hoegen , Uwe Hofmann , Carlota-Silvia Jaggle , Wolfgang Strittmatter , Jörg Stadlmüller , Siegfried Matzku
发明人： Ilka von Hoegen , Uwe Hofmann , Carlota-Silvia Jaggle , Wolfgang Strittmatter , Jörg Stadlmüller , Siegfried Matzku
IPC分类号： C12N15/09 , A61K20060101 , A61K38/00 , A61K38/16 , A61K38/18 , A61K38/19 , A61K38/20 , A61K39/00 , A61K39/295 , A61K39/395 , A61K39/44 , A61K47/48 , A61P35/00 , A61P35/04 , C07K20060101 , C07K14/52 , C07K14/525 , C07K14/54 , C07K14/55 , C07K16/00 , C07K16/28 , C07K16/30 , C07K16/42 , C07K16/46 , C07K19/00 , C12N20060101 , C12N15/13 , C12N15/19 , C12N15/55 , C12N15/62 , C12N15/64 , C12N15/72 , C12N15/79 , C12P21/02 , C12P21/08 , C12R1/19 , C12R1/91
CPC分类号： C07K14/525 , A61K38/00 , A61K47/6849 , A61K2039/505 , C07K14/5406 , C07K14/5418 , C07K14/55 , C07K16/2863 , C07K2319/00 , C12N2799/028
摘要： The present invention relates to new fusion proteins which consist of a tumor-associated targeting element preferentially a monoclonal antibody or a fragment thereof recognizing a molecule which is preferentially expressed on human tumor cells such as the human epidermal growth factor receptor (EGFR), and a biologically active ligand such as a growth and/or differentiation factor. The resulting fusion protein may be used to deliver the biologically active ligand to a specific target cell or tissue. The new immunoconjugates can be used in tumor therapy.
摘要翻译： 本发明涉及由肿瘤相关靶向元件优选单克隆抗体或其片段识别优先表达人肿瘤细胞如人表皮生长因子受体（EGFR）的分子组成的新融合蛋白，以及 生物活性配体如生长和/或分化因子。 所得的融合蛋白可用于将生物活性配体递送至特定的靶细胞或组织。 新的免疫缀合物可用于肿瘤治疗。
-
公开(公告)号：US5824782A
公开(公告)日：1998-10-20
申请号：US528523
申请日：1995-09-15
IPC分类号： C12N15/02 , A61K38/00 , A61K38/19 , A61K39/385 , A61K39/395 , A61K39/44 , A61K47/48 , A61P35/00 , A61P43/00 , C07K14/485 , C07K14/52 , C07K14/54 , C07K14/705 , C07K14/715 , C07K16/00 , C07K16/28 , C07K16/46 , C12N15/62 , C12P21/08 , C12R1/91 , C07K17/00 , C07K17/14
CPC分类号： A61K47/48415 , A61K47/48561 , Y02P20/582
摘要： The invention provides new immunoconjugates comprising a mono-clonal antibody or a fragment thereof specific for the human EGF-receptor molecule and a member of the chemokine family, preferably selected from the C-X-C family, e.g. lnterleukin-8 (IL-8). The immunoconjugates induce cytotoxic and chemotactic activity and are suitable for a targeted tumor therapy.
摘要翻译： 本发明提供了新的免疫偶联物，其包含对人EGF受体分子特异的单克隆抗体或其片段和趋化因子家族成员，优选选自C-X-C家族，例如， 白细胞介素-8（IL-8）。 免疫偶联物诱导细胞毒性和趋化活性，适用于靶向肿瘤治疗。
-
5.发明授权DNA encoding variant CD44 surface proteins associated with metastatic tumors 失效编码与转移性肿瘤相关的变体CD44表面蛋白的DNA
公开(公告)号：US5506119A
公开(公告)日：1996-04-09
申请号：US946497
申请日：1992-11-09
IPC分类号： A61K38/00 , A61K38/17 , A61K39/395 , A61P35/00 , A61P35/04 , C07K20060101 , C07K14/00 , C07K14/47 , C07K14/705 , C07K14/73 , C07K14/82 , C07K16/00 , C07K16/28 , C07K16/30 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/13 , C12P21/02 , C12P21/08 , G01N33/53 , G01N33/574 , G01N33/68 , A61K35/12 , C07K14/205
CPC分类号： C07K16/2884 , C07K14/705 , A61K38/00 , Y10S530/828
摘要： The presence of certain extracellular regions ("ECR") from human and rat variants of the CD44 membrane glycoprotein have been found to be associated with metastasis ability in tumor cells. Isolated polynucleotides encoding the ECRs permit expression of the ECR polypeptide, which in turn can be used as an antigen to obtain monoclonal antibodies that recognize the ECR polypeptide. The anti-ECR monoclonal antibodies have the ability to prevent metastasis by tumor cells that would otherwise metastasize and spread.
摘要翻译： PCT No.PCT / EP91 / 00614。 371日期：1992年11月9日 102（e）日期1992年11月9日PCT 1991年3月30日PCT公布。 公开号WO91 / 17248 1991年11月14日，CD44膜糖蛋白的人和大鼠变体的某些细胞外区域（“ECR”）的存在已被发现与肿瘤细胞的转移能力相关。 编码ECR的分离的多核苷酸允许表达ECR多肽，其又可以用作抗原以获得识别ECR多肽的单克隆抗体。 抗ECR单克隆抗体具有预防转移和扩散的肿瘤细胞转移的能力。
-
6.发明授权Process for the preparation of recombinant proteins in E. coli by high cell density fermentation 有权通过高细胞密度发酵在大肠杆菌中制备重组蛋白的方法公开(公告)号：US06410270B1
公开(公告)日：2002-06-25
申请号：US09077549
申请日：1998-11-16
申请人： Wolfgang Strittmatter , Siegfried Matzku , Dieter Riesenberg , Uwe Horn , Uwe Knüpeer , Marian Kujau , Rolf Wenderoth , Andreas Plückthun , Anke Krebber
发明人： Wolfgang Strittmatter , Siegfried Matzku , Dieter Riesenberg , Uwe Horn , Uwe Knüpeer , Marian Kujau , Rolf Wenderoth , Andreas Plückthun , Anke Krebber
IPC分类号： C12N1500
CPC分类号： C07K16/2863 , C12N15/72 , C12P21/02
摘要： The invention relates to a fed-batch fermentation process which uses special E. coli host/vector systems for the purpose of efficiently forming recombinant proteins, in particular recombinant antibody molecules, preferably antibody fragments such as miniantibodies. Under the given conditions, the E. coli cells are able to grow at a maximum specific growth rate up to very high cell densities. After the recombinant product formation has been switched on, it is only the formed product which restricts growth; there is no growth restriction due to substrates or metabolic by-products. High space-time yields of recombinant proteins can be achieved in this manner.
摘要翻译： 本发明涉及一种补料分批发酵方法，其使用特殊的大肠杆菌宿主/载体系统，以有效形成重组蛋白，特别是重组抗体分子，优选抗体片段，例如微型抗体。 在给定的条件下，大肠杆菌细胞能够以最大比生长速率生长直到非常高的细胞密度。 在重组产物形成开始后，只有限制生长的形成产物; 由于底物或代谢副产物没有生长限制。 可以以这种方式实现重时蛋白质的高空时产量。
-
公开(公告)号：US5885575A
公开(公告)日：1999-03-23
申请号：US478882
申请日：1995-06-07
IPC分类号： A61K38/00 , A61K38/17 , A61K39/395 , A61P35/00 , A61P35/04 , C07K20060101 , C07K14/00 , C07K14/47 , C07K14/705 , C07K14/73 , C07K14/82 , C07K16/00 , C07K16/28 , C07K16/30 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/13 , C12P21/02 , C12P21/08 , G01N33/53 , G01N33/574 , G01N33/68 , G01N33/58
CPC分类号： C07K16/2884 , C07K14/705 , A61K38/00 , Y10S530/828
摘要： The inventon relates to antibodies that react with a variant epilope in the extracellular region of a variant CD44 polypeptide, wherein the variant epitope has the amino acid sequence:I S S T I S T T P R A P D H T K Q N Q D W T Q W N P S H S N P EV L L Q T T T R M T D V D R N G T T A Y E G N W N P E A H P P LI H H E H H E E E E T P H S T S T I O A T P S S T T E E T A T QK E Q W F G N R W H E G Y R Q T P R E D S H S T T G T A A A S AH T S H P M Q G R T T P S P E D S S W T D F F N P I S H P M G RG H Q A G R R (residues 53-219 of SEQ ID NO:4). Methods of using the antibodies to identify variant epitopes also are provided.
摘要翻译： 所述inventon涉及用在一种变型CD44多肽的细胞外区域的变体epilope，其中所述变体的表位具有氨基酸序列反应的抗体：ISSTISTTPRAPDHTKQNQDW TQWNPSHSNPEVLLQTTTRMT DVDRNGTTAYEGNWNPEAHPP LIHHEHHEEEETPHSTSTIOA TPSSTTEETATQKEQWFGNRW HEGYRQTPREDSHSTTGTAAA SAHTSHPMQGRTTPSPEDSSW TDFFNPISHPMGRGHQAGRR（残基的SEQ ID NO 53-219：4 ）。 还提供了使用抗体鉴定变异表位的方法。
-
8.发明授权Human and rat variants of glycoprotein CD44 containing an additional extracellular domain associated with metastatic potential 失效含有与转移潜能相关的额外细胞外结构域的糖蛋白CD44的人和大鼠变体
公开(公告)号：US5760178A
公开(公告)日：1998-06-02
申请号：US483322
申请日：1995-06-07
IPC分类号： A61K38/00 , A61K38/17 , A61K39/395 , A61P35/00 , A61P35/04 , C07K20060101 , C07K14/00 , C07K14/47 , C07K14/705 , C07K14/73 , C07K14/82 , C07K16/00 , C07K16/28 , C07K16/30 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/13 , C12P21/02 , C12P21/08 , G01N33/53 , G01N33/574 , G01N33/68 , C07K1/00 , C07K17/00 , C12P21/06
CPC分类号： C07K16/2884 , C07K14/705 , A61K38/00 , Y10S530/828
摘要： A monoclonal antibody (MAb1.1ASML) directed against a surface glycoprotein of the metastasizing rat pancreatic carcinoma cell line BSp73ASML, was used to identify and isolate a complementary DNA (cDNA) clone capable of encoding for a glycoprotein with partial homology to CD44, a presumed adhesion molecule. This clone, which was subsequently designated pMeta-1, contains an additional extracellular domain of 162 amino acids inserted into the CD44 protein between amino acid positions 223 and 247 (by analogy to human and murine CD44). This new variant was expressed only in the metastasizing cell lines of two rat tumors, the pancreatic carcinoma BSp73 and the mammary adenocarcinoma 13762NF; it was not expressed in non-metastasizing tumor cell lines nor in normal rat tissues. Overexpression of pMeta-1 in the nonmetastasizing BSp73AS cell line suffices to establish full metastatic behavior. The variant-specific rat CD44 sequence was used to isolate a cDNA clone encoding for a human homologue as well.
摘要翻译： 使用针对转移性大鼠胰腺癌细胞系BSp73ASML的表面糖蛋白的单克隆抗体（MAb1.1ASML）来鉴定和分离能够编码与CD44具有部分同源性的糖蛋白的互补DNA（cDNA）克隆，假定 粘附分子。 随后称为pMeta-1的克隆在氨基酸位置223和247（类似于人和鼠CD44）之间含有插入到CD44蛋白中的162个氨基酸的另外的胞外结构域。 该新变体仅在两个大鼠肿瘤的转移细胞系，胰腺癌BSp73和乳腺腺癌13762NF中表达; 在非转移性肿瘤细胞系和正常大鼠组织中未表达。 非特异性BSP73AS细胞系中pMeta-1的过度表达足以建立完全转移的行为。 变体特异性大鼠CD44序列用于分离编码人同源物的cDNA克隆。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.025 秒)
